CDXC vs. ACB, MDWD, FTLF, BTMD, NAII, MTEX, MNMD, USNA, CGC, and MGNX
Should you be buying ChromaDex stock or one of its competitors? The main competitors of ChromaDex include Aurora Cannabis (ACB), MediWound (MDWD), FitLife Brands (FTLF), biote (BTMD), Natural Alternatives International (NAII), Mannatech (MTEX), Mind Medicine (MindMed) (MNMD), USANA Health Sciences (USNA), Canopy Growth (CGC), and MacroGenics (MGNX). These companies are all part of the "medical" sector.
Aurora Cannabis (NASDAQ:ACB) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment.
ChromaDex has lower revenue, but higher earnings than Aurora Cannabis. ChromaDex is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 15.4% of ChromaDex shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 10.6% of ChromaDex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, ChromaDex had 3 more articles in the media than Aurora Cannabis. MarketBeat recorded 14 mentions for ChromaDex and 11 mentions for Aurora Cannabis. ChromaDex's average media sentiment score of 1.13 beat Aurora Cannabis' score of -0.22 indicating that Aurora Cannabis is being referred to more favorably in the media.
ChromaDex received 152 more outperform votes than Aurora Cannabis when rated by MarketBeat users. Likewise, 63.99% of users gave ChromaDex an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.
ChromaDex has a consensus price target of $6.00, indicating a potential upside of 77.51%. Given Aurora Cannabis' higher possible upside, analysts plainly believe ChromaDex is more favorable than Aurora Cannabis.
ChromaDex has a net margin of -4.24% compared to ChromaDex's net margin of -48.82%. Aurora Cannabis' return on equity of -12.61% beat ChromaDex's return on equity.
Aurora Cannabis has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500.
Summary
ChromaDex beats Aurora Cannabis on 12 of the 16 factors compared between the two stocks.
Get ChromaDex News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ChromaDex Competitors List
Related Companies and Tools
